Document is current
Any future updates will be listed below
-
Authors
Deflaux, Nicole https://orcid.org/0000-0002-9421-8048
Selvaraj, Margaret Sunitha https://orcid.org/0000-0002-2751-9254
Condon, Henry Robert
Mayo, Kelsey https://orcid.org/0000-0002-2382-1376
Haidermota, Sara
Basford, Melissa A.
Lunt, Chris https://orcid.org/0000-0002-8504-0735
Philippakis, Anthony A. https://orcid.org/0000-0001-6953-3794
Roden, Dan M.
Denny, Joshua C.
Musick, Anjene
Collins, Rory
Allen, Naomi https://orcid.org/0000-0003-1938-5038
Effingham, Mark https://orcid.org/0000-0003-0174-4717
Glazer, David https://orcid.org/0000-0002-6407-8646
Natarajan, Pradeep https://orcid.org/0000-0001-8402-7435
Bick, Alexander G. https://orcid.org/0000-0001-5824-9595
- License Information
-
More Information
Article History
Received: 5 December 2022
Accepted: 24 August 2023
First Online: 5 September 2023
Competing interests
: P.N. reports investigator-initiated grants from Amgen, Apple, AstraZeneca, Boston Scientific, and Novartis, personal fees from Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Novartis, Roche/Genentech, is a co-founder of TenSixteen Bio, is a shareholder of geneXwell and TenSixteen Bio, and spousal employment at Vertex, all unrelated to the present work. A.G.B. is a co-founder and shareholder of TenSixteen Bio unrelated to the present work. N.D. and D.G. are employees of Verily Life Sciences and may own stock as part of the standard compensation package. A.P. serves as a Google Ventures (GV) venture partner and holds an equity interest in certain of GV’s affiliated investment funds. A.P. has also received funding from Verily, MSFT, Intel, IBM, Bayer, Pfizer, Astra Zeneca, and Biogen. The remaining authors declare no competing interests.
